Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -31.08
- Piotroski Score 2.00
- Grade Neutral
- Symbol (XBIO)
- Company Xenetic Biosciences, Inc.
- Price $4.11
- Changes Percentage (4.7%)
- Change $0.19
- Day Low $3.90
- Day High $4.20
- Year High $5.20
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.93
- Trailing P/E Ratio -1.33
- Forward P/E Ratio -1.33
- P/E Growth -1.33
- Net Income $-4,134,578
Income Statement
Quarterly
Annual
Latest News of XBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo Finance
REGENXBIO Inc. is a US biotechnology company specializing in gene therapies using NAV Technology Platform to treat genetic defects. They have various product candidates in development for diseases lik...
By Yahoo! Finance | 3 months ago -
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History
REGENXBIO Inc. is a US-based biotechnology company specializing in gene therapies using its NAV Technology Platform. They have multiple gene therapy products in the pipeline, including treatments for ...
By Yahoo! Finance | 3 months ago -
Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
A list of Top 10 Small-Cap Stocks with Highest Upside Potential includes REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotech firm focusing on gene therapy. Analysts predict a 226....
By Yahoo! Finance | 4 months ago
